Novartis MS Therapy FTY720 Enters Phase III With Lower, Untested Dose
Executive Summary
Following delays due to FDA safety concerns, Novartis is moving forward with Phase III trials of its oral multiple sclerosis therapy FTY720, although one of the two doses being evaluated lacks clinical data to support its efficacy
You may also be interested in...
Mid-Cap Biotechs Rise In ’06; Small Firms Face “Burden” Of New Products
Disappointing product launches by CV Therapeutics and NitroMed underscore the challenges that small manufacturers face in trying to successfully bring new products to market
NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue